Pharmaceutical composition consisting of calcium channel blocker and serotonin reuptake inhibitor

A technology of calcium channel blocker and composition, applied in the field of pharmacy, can solve the problems of not paying attention to the mental and psychological health of hypertensive patients, the effect of antihypertensive treatment, lack of sufficient cognition, etc., so as to relieve depression or anxiety. Effect

A technology of calcium channel blocker and composition, applied in the field of pharmacy, can solve the problems of not paying attention to the mental and psychological health of hypertensive patients, the effect of antihypertensive treatment, lack of sufficient cognition, etc., so as to relieve depression or anxiety. Effect

CN112336866APending Publication Date: 2021-02-09耿庆山 +1

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition consisting of calcium channel blocker and serotonin reuptake inhibitor
  • Pharmaceutical composition consisting of calcium channel blocker and serotonin reuptake inhibitor
  • Pharmaceutical composition consisting of calcium channel blocker and serotonin reuptake inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1. preparation amlodipine 5mg / paroxetine 20mg sheet (1000 sheet quantity)

[0031]

[0032]

[0033] Preparation method: pass the raw materials and auxiliary materials of the prescription amount through an 80-mesh sieve, and set aside. Take 5g of amlodipine and 20g of paroxetine and mix them uniformly according to the method of equal increase, add lactose, microcrystalline cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl cellulose respectively according to the prescription amount, and mix evenly according to the method of equal increase , use 5% povidone K30-95% ethanol solution to make soft material, granulate with 20 mesh sieve, dry at 40°C for about 2 hours, granulate with 18 mesh sieve, control the water content of the granules to 2-3%, dry the granules Weigh, add magnesium stearate in a ratio of 1.0%, and the semi-finished product is detected, and the tablet weight is calculated according to the content of the total mixed pa...

Embodiment 2

[0034] Embodiment 2. preparation felodipine 5mg / paroxetine 20mg sheet (1000 sheet quantity)

[0035]

[0036] Preparation method: pass the raw materials and auxiliary materials of the prescription amount through an 80-mesh sieve, and set aside. Take 5g of felodipine and 20g of paroxetine and mix them uniformly according to the method of equal increase, add lactose, microcrystalline cellulose, sodium carboxymethyl starch and croscarmellose sodium respectively according to the prescription amount, and mix them evenly according to the method of equal increase. Mix, then mix with glyceryl behenate evenly, test the semi-finished product, measure the content, and directly compress it into 1000 tablets with a tablet machine.

Embodiment 3

[0037] Embodiment 3. preparation lacidipine 4mg / paroxetine 20mg sheet (1000 sheet quantity)

[0038]

[0039] Preparation method: pass the raw materials and auxiliary materials of the prescription amount through an 80-mesh sieve, and set aside. Take 4g of lacidipine and 20g of paroxetine and mix them uniformly according to the method of equal increase, add lactose, microcrystalline cellulose, sodium carboxymethyl starch and croscarmellose sodium respectively according to the prescription amount, Mix, then mix with glyceryl behenate evenly, test the semi-finished product, measure the content, and directly compress it into 1000 tablets with a tablet machine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing a calcium channel blocker (CCB for short) and paroxetine. The pharmaceutical composition is composed of a medicinal dose of CCB, a medicinal dose of paroxetine and a pharmaceutically acceptable carrier. The invention provides an application of the pharmaceutical composition in preparation of a medicine for treating hypertension complicated with anxiety state (symptom) or depression state (symptom). Through the implementation of the invention, the suitable therapeutic medicine is provided for patients with the physical and mentaldiseases, the medication compliance of the patients can be improved, the curative effect is improved, the life quality is improved, and the medical cost is reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition composed of a calcium channel blocker and paroxetine, and an application of the pharmaceutical composition in preparing medicine for treating hypertension complicated with anxiety or depression. The present invention belongs to the field of pharmacy. Background technique [0002] Hypertension is one of the most common chronic diseases and the most important risk factor for cardiovascular and cerebrovascular diseases. Once stroke, myocardial infarction, heart failure and other complications occur, the rate of disability and death is high. The main treatment goal of hypertension is to minimize the risk of cardiovascular complications and death, and it is necessary to treat all reversible risk factors, subclinical target organ damage, and various coexisting diseases [Revised Committee of Guidelines for the Prevention and Treatment of Hypertension in China. Guidelines for Prevention and Treatment of Hy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
09 Feb 2021
Publication
CN112336866A
IPC
A61K45/06; A61K31/4525; A61K31/4422; A61P9/12; A61P25/22; A61P25/24
CPC
A61K45/06; A61K31/4525; A61K31/4422; A61P9/12; A61P25/22; A61P25/24; A61K2300/00
Inventors
耿庆山; 张磊